Overview

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2040-12-31

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Phase:

PHASE2

Details

Lead Sponsor:

Eikon Therapeutics

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

130-nm albumin-bound paclitaxel
Carboplatin
Cisplatin
CP protocol
pembrolizumab
Pemetrexed